Update July 30, 2018
Mitochondrial diseases encompass at least 40 diverse disorders that are grouped because of their links to mitochondrial failure. These diseases can occur following inheritance or spontaneous mutations in mitochondrial or nuclear DNA that lead to altered functions of the mitochondrial proteins (or RNA). Depending on the target cell and/or tissues affected, symptoms resulting from mitochondrial diseases may include altered motor control; altered muscle output; gastrointestinal dysfunction; altered growth; diabetes; seizures; visual/hearing problems; lactic acidosis; developmental delays; and susceptibility to infection or cardiac, liver, and respiratory disease. Although there is evidence for tissue-specific isoforms of mitochondrial proteins, mutations in these proteins do not fully explain the highly variable patterns or targeted organ systems observed with mitochondrial diseases.
THERAPEUTIC HIGHLIGHTS
With the diversity of disease types and the overall importance of mitochondria in energy production, it is not surprising that there is no single cure for mitochondrial diseases and focus remains on treating the symptoms when possible. For example, in some mitochondrial myopathies (ie, mitochondrial diseases associated with neuromuscular function), physical therapy may help extend the range of movement of muscles and improve dexterity.
The enzyme complexes responsible for oxidative phosphorylation illustrate the interactions between the products of the mitochondrial genome and the nuclear genome. For example, complex I, reduced nicotinamide adenine dinucleotide dehydrogenase (NADH), is made up of 7 protein subunits coded by mitochondrial DNA and 39 subunits coded by nuclear DNA. Complex II, succinate dehydrogenase-ubiquinone oxidoreductase; complex III, ubiquinonecytochrome c oxidoreductase; and complex IV, cytochrome c oxidase, act with complex I, coenzyme Q, and cytochrome c to convert metabolites to CO2 and water. Complexes I, III, and IV pump protons (H+) into the intermembrane space during this electron transfer. The protons then flow down their electrochemical gradient through complex V, ATP synthase, which harnesses this energy to generate ATP.
In a retrospective study of over 1 million patients, ulnar neuropathy (persisting for more than 3 months) occurred in approximately 1 in 2700 patients.1 Of interest, initial symptoms were most frequently noted more than 24 hr after a surgical procedure. Risk factors included male gender, hospital stay greater than 14 days, and very thin or obese body habitus. More than 50% of these patients regained full sensory and motor function within 1 yr.
Anesthetic technique was not implicated as a risk factor; 25% of patients with ulnar neuropathy underwent monitored care or lower extremity regional technique.
The ASA Closed Claims Project findings support most of these results, including the delayed onset of symptoms and the lack of relationship between anesthesia technique and injury. This study also noted that many neuropathies occurred despite notation of extra padding over the elbow area, further negating compression as a possible mechanism of injury. Finally, the ASA Closed Claims Project investigators found no deviation from the standard of care in the majority of patients who manifested nerve damage perioperatively.
Content 3